Main finding: Adalimumab was associated with a lower rate of treatment failure, but higher incidence of adverse events in children and adolescents with active JIA-associated uveitis on a stable dose of methotrexate
Purpose: Evaluate safety and efficacy of adalimumab in JIA-associated uveitis
Type: Randomized controlled Trial
Condition: JIA-associated uveitis
Participants: ≥2 years, active JIA-associated uveitis despite being on methotrexate and glucocorticoid therapy.
n=90
Intervention:
Group 1: Adalimumab (20mg or 40mg subcut every 2 weeks)
Group 2: Placebo
Both groups on a stable dose of weekly methotrexate.
Adalimumab
Placebo
Treatment failure
27%
60%
All adverse events (events per patient-year)
10.07
6.51
Serious adverse events (events per patient-year)
0.29
0.19
Share This Article :
Please provide feedback on content published. Thank you.
Source Archive